Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (223)
  2. Journal Article (82)
  3. Review (16)
  4. Research Letter (11)
  5. Correspondence (5)
  6. Editorial (4)
  7. Guidelines (3)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (171)
  2. Department of Medicine (168)
  3. Center for Hematologic Malignancies (161)
  4. Graduate Medical Education (151)
  5. Myeloma (149)
  6. GME, Medicine (142)

More Groups

People
  1. Alexander Lesokhin (129)
  2. Kylee Maclachlan (127)
  3. Sham Mailankody (113)
  4. Urvi Shah (110)
  5. Carlyn Rose Tan (105)
  6. Neha Korde (103)

More People

Years
  1. 2025 (42)
  2. 2024 (97)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (110)
  2. Clinical Lymphoma, Myeloma and Leukemia (81)
  3. Journal of Clinical Oncology (32)
  4. Blood Cancer Journal (16)
  5. Blood Advances (15)
  6. British Journal of Haematology (8)

More Publications

Publishers
  1. American Society of Hematology (125)
  2. Elsevier Inc. (94)
  3. American Society of Clinical Oncology (32)
  4. Nature Publishing Group (24)
  5. Elsevier Science, Inc. (10)
  6. John Wiley & Sons (9)

More Publishers

Results (345)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies
    Journal Article

    Howard, A. J.; Concepcion, I.; Wang, A. X.; Hamadeh, I. S.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Korde, N.; Lesokhin, A. M.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
    Journal Article

    Firestone, R. S.; Socci, N. D.; Shekarkhand, T.; Zhu, M.; Qin, W. G.; Hultcrantz, M.; Mailankody, S.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Journal Article

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M. L.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
    Journal Article

    Nooka, A. K.; Kaufman, J. L.; Rodriguez, C.; Jakubowiak, A.; Efebera, Y.; Reeves, B.; Wildes, T. M.; Holstein, S. A.; Anderson, L. D. Jr; Badros, A.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN
    Journal Article

    Silbermann, R.; Laubach, J.; Kaufman, J. L.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Chari, A.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
    American Journal of Hematology (2024)

    Fulltext@MSK | Save
  • Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
    Journal Article

    Nath, K.; Shekarkhand, T.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D. J.; Landau, H. J.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
    Journal Article

    Firestone, R. S.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Qin, W. G.; Patel, D.; Tan, C. R.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
    Journal Article

    Costa, B. A.; Flynn, J.; Nishimura, N.; Devlin, S. M.; Farzana, T.; Rajeeve, S.; Chung, D. J.; Landau, H. J.; Lahoud, O. B.; Scordo, M.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Adjusted indirect treatment comparison of progression-free survival with D-Rd and VRd based on MAIA and SWOG S0777 individual patient-level data
    Journal Article

    Durie, B. G. M.; Kumar, S. K.; Ammann, E. M.; Fu, A. Z.; Kaila, S.; Lam, A.; Usmani, S. Z.; Facon, T.
    Advances in Therapy (2024)

    Fulltext@MSK | Save
  • International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
    Guidelines

    Rodriguez-Otero, P.; Usmani, S.; Cohen, A. D.; van de Donk, N. W. C. J.; Leleu, X.; Gállego Pérez-Larraya, J.; Manier, S.; Nooka, A. K.; Mateos, M. V.; Einsele, H.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save